Medpage Today on MSN5mon
Cytokine Release Syndrome and Neurotoxicity After CAR T-Cell Therapy
The most frequent of these immune-mediated toxicities are cytokine release syndrome (CRS) and immune effector ... Jain ...
Healio6d
Siltuximab reduces severity of cytokine release syndrome, ICANS after CAR T-cell therapy
Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, ...
Medscape12d
NHL: Are Bispecific Antibodies a Safe Treatment?
TOPLINE: Bispecific antibodies (BsAbs) demonstrated a manageable safety profile in patients with non-Hodgkin lymphoma (NHL), with 48% prevalence of all-grade cytokine release synd ...